Aragen Bioscience and Getinge’s Successful Validation of Single-Use Production Reactors

• Aragen Bioscience, a Contract Research Development and Manufacturing Organization (CRDMO), and Getinge, a Swedish life sciences service provider, have announced the successful validation of Getinge’s Single-Use Production Reactors (SUPR) for large-scale recombinant antibody production.

• The validation study was conducted at Aragen’s R&D facility in Morgan Hill, CA, demonstrating the SUPR Bioreactor’s performance in generating high-quality recombinant antibodies.

Aragen Bioscience and Getinge, a Swedish life sciences service provider, have announced a successful validation of Getinge’s Single-Use Production Reactors (SUPR) for large-scale recombinant antibody production. This collaboration combines Aragen’s biopharmaceutical manufacturing expertise and Getinge’s single-use technology, aiming to enable seamless production of large-scale batches.

The validation study was conducted at Aragen’s R&D facility in Morgan Hill, CA. It demonstrated the SUPR Bioreactor’s performance in generating high-quality recombinant antibodies. The reactor is designed to be a single-use alternative to traditional stainless-steel bioreactors at the pilot and production scale. This allows the upstream process to continue from research to production with one trusted single-use platform. R&D and process optimization performed in the AppliFlex ST or Applikon Bio can now be scaled up using the SUPR.

Dr. Subodh Deshmukh, CEO, Aragen Bioscience, expressed satisfaction with the collaboration with Getinge. He stated, “This partnership showcases our commitment to providing our clients with cutting-edge technology and proven capabilities to accelerate their drug development programs.” He further added that Getinge’s 50L and 250L single-use bioreactor platforms are now available at Aragen to support the growing demand for large-scale recombinant antibody production.

Timo Walvoort, Director of Research & Development, Getinge, also expressed his views on the collaboration. He said, “The collaboration with Aragen has been instrumental in the development of this best-in-class, next generation, single-use production bioreactor system. Through closely working together, we have developed the world’s first single-use true bioreactor, with unparalleled ease-of-use.”